Browsing Tag

Day One Biopharmaceuticals

Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of…

Eli Pacheco Jun 4, 2023 0

Overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated RANO-HGG evaluable patients The Company expects to complete rolling NDA submission in…

Health

Day One Announces Pricing of Upsized Public Offering of Common Stock

Eli Pacheco Jun 15, 2022 0

SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and…

Health

Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib…

Eli Pacheco Jun 13, 2022 0

Data show an overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% in the first 22 evaluable patients treated with monotherapy tovorafenib Topline results from the full…

Health

Day One Reports Second Quarter 2021 Financial Results and Corporate Progress

Eli Pacheco Aug 11, 2021 0

DAY101 Granted Rare Pediatric Disease Designation from FDA DAY101 Granted Orphan Designation from European Commission Dosed the First Patients in Pivotal FIREFLY-1 Clinical Trial of…